Peer-reviewed veterinary case report
Lokivetmab treatment reduces skin water loss in dogs with atopic
By Szczepanik, Marcin et al.·Published in Veterinary dermatology·2019·Faculty of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The influence of treatment with lokivetmab on transepidermal water loss (TEWL) in dogs with spontaneously occurring atopic dermatitis.
- Species:
- dog
Plain-English summary
A group of ten dogs with atopic dermatitis (a common skin condition that causes itching and inflammation) were treated with lokivetmab, an injectable medication, over 12 weeks. Owners noticed a significant reduction in itching and skin lesions, as measured by a specific scoring system. Additionally, the amount of water lost through the skin decreased, indicating improved skin health. This suggests that lokivetmab is effective in managing symptoms of atopic dermatitis in dogs, leading to better comfort and skin condition.
People also search for: dog atopic dermatitis treatment · lokivetmab for dogs · why is my dog itching · dog skin problems solutions · canine dermatitis medication
Abstract
BACKGROUND: Atopic dermatitis (AD) is one of the most common skin diseases in dogs. Monitoring the progress of treatment may include assessment of lesion severity by use of Canine Atopic Dermatitis Extent and Severity Index (CADESI), assessment of pruritus and measurement of biophysical parameters of the skin. HYPOTHESIS: This study aimed to assess changes in transepidermal water loss (TEWL) during 12 weeks of treatment with lokivetmab and its correlation with the CADESI-04 and the severity of pruritus. ANIMALS: Ten client-owned dogs with canine AD. METHODS AND MATERIALS: The animals were administered lokivetmab three times at four week intervals. Pruritus and CADESI-04 were assessed, and TEWL was measured at six body regions, on Day 0 and repeated at weeks 4, 8 and 12. RESULTS: There was a significant decrease in the CADESI-04 score, the severity of pruritus and the mean TEWL between baseline and each of the time points. TEWL also decreased in the majority of body sites examined. Significant correlations between the CADESI-04 and mean TEWL (r = 0.519, P = 0.0003), and between pruritus severity and mean TEWL (r = 0.517, P = 0.0003), were found. CONCLUSIONS AND CLINICAL SIGNIFICANCE: Overall TEWL decreased during lokivetmab treatment but not at all body sites. If TEWL is used to assess the effectiveness of a treatment, a mean TEWL score should be calculated from several areas of the body.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31090122/